Weitz & Luxenberg is taking cases of cancer in both children and adults who took the popular heartburn medication Zantac (ranitidine), following an FDA announcement in September of this year that preliminary tests of some lots of Zantac were found to have traces of NDMA, a known carcinogen.
Risks of Zantac
Zantac, first approved in the 1980s and one of the first medications to exceed $1 billion in annual sales, has become the subject of FDA scrutiny and recalls around the world.
In June, a Connecticut-based lab alerted the Food and Drug Administration (FDA) that it found NDMA in ranitidine products. The FDA performed its own laboratory analyses of Zantac and ranitidine products, and is asking companies whose ranitidine products exceed its defined acceptable limits of NDMA to voluntary recall these affected products. In addition, several pharmaceutical companies and retailers including CVS, Walgreens, and Walmart, have pulled ranitidine products from their shelves, and the FDA has noted that people who use the over-the-counter formulations of Zantac or ranitidine could consider using other heartburn medications.
A 2016 study examining urine outputs of patients given ranitidine found that participants’ urinary NDMA excretion increased significantly over 24 hours after taking the drug.
W&L Can Help Cancer Patients and their Families
Weitz & Luxenberg encourages anyone who has developed the following cancers after using Zantac continuously for two years as a child or five years as an adult to contact the firm using the online form on this page or by calling (800) 476-6070 for a free consultation:
- Liver cancer.
- Bladder cancer.
- Bile duct cancer.
- Colorectal cancer.
- Kidney cancer.
- Stomach cancer.
W&L would also like to hear from the families of cancer patients who have passed away from the cancers listed above after continuous Zantac use.
*Past performance is no guarantee of future results. The settlements in which Weitz & Luxenberg played leadership roles included patients not represented by W&L.